
    
      This is a prospective, open-label, multi-institutional, positive medicine control of equal
      rank comparative study of neoadjuvant double-drug chemotherapy with platinum plus anlotinib
      hydrochloride in stage III(N2) non-small-cell lung cancer.The main purpose of this study was
      to compare the difference in N2 downgrade rate of lymph node and resectability rate between
      the experimental and control groups, to evaluate the efficacy of anlotinib hydrochloride, and
      to observe and evaluate its objective response rate(ORR)ï¼ŒDisease-free Survival (DFS)and
      overall survival(OS).
    
  